Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Journal of Managed Care & Specialty Pharmacy|November 24, 2021
Use of prescriber requirements among US commercial health plansKelly Lenahan, Ari D Panzer, Rebecca Gertler, et al.Journal of Managed Care & Specialty Pharmacy|March 29, 2023
The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverageAri D Panzer, Michael Ingham, Silas Martin, et al.Journal of Managed Care & Specialty Pharmacy|August 2, 2021
Limited role of patient input in specialty drug coverage policiesBrittany D'Cruz, Jennifer S Graff, Ari D Panzer, et al.Journal of Managed Care & Specialty Pharmacy|August 24, 2022
Characterizing health plan evidence review practicesAri D Panzer, Daniel E Enright, Jen Graff, et al.The American Journal of Managed Care|October 18, 2019
Variation in US private health plans' coverage of orphan drugsJames D Chambers, Ari D Panzer, David D Kim, et al.Health Affairs (Project Hope)|November 5, 2019
Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug CoverageJames D Chambers, Ari D Panzer, Elle F Pope, et al.Pharmacoepidemiology and Drug Safety|March 27, 2020
What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?Ari D Panzer, Nikoletta M Margaretos, Rachel C Lai, et al.Journal of Medical Economics|September 20, 2021
Variation in access to hemophilia A treatments in the United StatesNikoletta M Margaretos, Anisha M Patel, Ari D Panzer, et al.The American Journal of Managed Care|April 14, 2022
Patients' access to 2018 FDA-approved drugs 1 year post approvalAri D Panzer, Nikoletta M Margaretos, Naomi Bridger, et al.Journal of Managed Care & Specialty Pharmacy|June 5, 2023
Specialty drug coverage varies between health plans' medical and pharmacy benefit policiesA Alex Levine, Ari D Panzer, Teresa L Kauf, et al.Pageof 2